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Précis 25
Initiators of contraceptive implant are more likely to perceive weight gain compared to the control group; 26 however, no differences in objective weight gain were found. 27
Introduction 49
Many clinicians and patients believe that hormonal contraception, including progestin-only implants, 50 causes weight gain. Product labeling for implants lists weight gain as a commonly-reported side effect 51 and as a leading cause of method discontinuation (1, 2) . This labeling, which was based on non-52 comparative clinical trials or those comparing two implant types (3) , could simply reflect background 53 noise as adult women tend to gain weight over time (4) (5) (6) (7) (8) . Given the lack of randomized trials with a non-54 hormonal control arm (9), the causal effect of implants on weight gain is unknown. 55
56
The U.S. Centers for Disease Control and Prevention (CDC) recommends that clinicians counsel implant 57 users on possible side effects and consider measuring patient weight at baseline to monitor changes (10). 58
However, attempts to manage patient expectations by counseling new users on potential side effects could 59 have the opposite effect than that intended. Counseling women on possible weight gain could lead to the 60 perception of weight gain, even in the absence of a true effect, through the power of negative suggestion, 61
i.e., the nocebo effect (11). 62
63
The perception of negative side effects is an important cause of method discontinuation or imperfect 64 adherence to contraception. Discontinuation of implants is common, with large studies in the U.S. and the 65 U.K. reporting discontinuation rates of 12-17% at one year (12,13) and 31% at two years (14). This 66 discontinuation is a critical public health issue as implants are a highly effective method (15) and 67 discontinuers often switch to a less effective method or use no method (16). Establishing the true effect of 68 implants on weight is needed to be able to provide evidence-based counseling to women. Our objective 69 was to compare changes in weight (perceived and measured) between women randomized to either start 70 the implant or to delay its initiation. 71 either receive it at enrollment ("implant" arm) or after three months of follow up ("control" arm). The 78 two-rod subdermal contraceptive implant contains the same amount of active ingredient as in the implant 79 Jadelle (18) . Participants were non-pregnant, HIV-negative women 18-44 years of age who met the 80 following requirements: without contraindications to the implant, were not already using a long-acting 81 contraceptive method or planning to start one in the next three months, and provided written consent to 82 enroll. During the study consenting process, women were informed about the implant's potential side 83 effects, including weight gain. At the time of implant initiation, participants received a brochure listing 84 these side effects. At one and three months, participants were weighed and completed a face-to-face 85 questionnaire, which included a question about perceived changes in health since their last visit: "Have 86 you noticed any changes in your health since your last visit?" "Weight gain" or "weight loss" were two 87 possible responses listed. Sample size calculations were based on the primary study objective (17). 88
72
Materials and Methods
Ethical review boards at the Jamaica Ministry of Health, the CDC and the University of West Indies 89 approved the study. The trial was registered ClinicalTrials.gov, number NCT01684358. 90
91
Because the weight data were not normally distributed, we used one-sided Wilcoxon-Mann-Whitney tests 92 (19) to evaluate whether the implant arm had greater median gain in weight between enrollment and the 93 two follow-up visits. As a secondary evaluation, we compared the risk of gaining >2 kg (a common 94 weight outcome in contraceptive research (20)) at either follow-up visit by study arm using logistic 95 regression with generalized estimating equations (GEE) to account for multiple visits from individual 96 women. We also calculated one-sided chi-squared tests to test whether the implant arm was more likely15-1949R1 Gallo 12-7-15v2 6 than the control arm to perceive weight gain, and less likely to perceive weight loss, at the two follow-up 98 visits. All analyses used an intent-to-treat approach. 99 100
Results
101
Although 555 women were recruited, 133 did not meet the screening criteria and 8 declined to consent 102 (Figure 1) . Thus, 414 women were enrolled and randomized to the implant (N=208) or control arm 103 (N=206). The one-month and three-month visits were completed by 203 women in the implant arm and 104 by 198 and 186 women, respectively, in the control arm. As previously reported, participants had a 105 median of 25 years of age and most had completed high school (69%) and had never been married (71%) 106 (Table 1) . Women in the control arm gained a median of 0.0 kg by both follow-114 up visits. These median changes in weight were not statistically significantly different between arms at 115 the one-month (p=0.44) or three-month visit (p=0.27). Similarly, women in the implant arm were not at 116 higher risk of gaining >2 kg than those in the control arm (odds ratio [OR], 0.9; 95% confidence interval 117
[CI], 0.6-1.3). We also evaluated differences between arms in the percentage change in body mass index 118 and found no difference in interpretation (data not reported). 119
120
Few participants reported having gained or lost weight since their last visit (Table 1) . Perceived weight 121 gain did not differ between arms at the one-month visit (p=0.10) but at the three-month visit, more15-1949R1 Gallo 12-7-15v2 7 women in the implant arm (15.3%) reported gaining weight than in the control arm (4.3%) (p=0.01). 123
Perceived weight loss did not differ by arm at either follow-up visit. Most of the visits (63%; 38/60) in 124 which the woman perceived weight gain were not accompanied by a measured gain of >2 kg. Perceived 125 weight gain was associated with having a measured gain of 2 kg among women in the implant arm (OR, 126 3.5; 95% CI, 1.8-6.9) but not among women in the control arm (OR, 2.1; 95% CI, 0.7-6.3). There was no 127 relationship between women's overall weight and their perception of weight gain (OR, 1.01; 95% CI, 128
1.00-1.02). 129
130
Discussion 131
We found no evidence that women initiating a levonorgestrel subdermal implant gained significantly 132 more weight compared to control women over 3 months from insertion. Median changes in weight, 133 overall, were negligible. A previous analysis of 11 trials of the single-rod etonogestrel implant that 134 studied 942 women for ≥2 years found that most women gained weight: 0.1 to 2.5 kg (25%), 2.6 kg to 5.0 135 kg (24%), 5.1 to 7.5 kg (9%), and >7.5 kg (11%) (21) . However, these gains could reflect background 136 noise; the annual weight increase in adult women has been estimated at 0.4 to 0.6 kg (4,5), 0.1 to 0.2 137 kg/m 2 (body mass index) (6,7), and 0.5% change in weight (8). Despite a lack of observed difference in 138 weight between study arms in the present study, women using the implant were more likely to perceive 139 weight gain than those in the control arm. This finding underscores the power of expectations on patient 140
experiences. 141 142
The main limitation of the present trial is its short follow-up, which could have been inadequate for 143 detecting gains. For ethical reasons, the control arm was offered the implant after three months of follow-144 up, an interval similar to the delay that the target population typically experienced in accessing 145 contraceptive methods. Another limitation is that weight was not a primary trial outcome, and methods 146
were not implemented to standardize its measurement, such as weighing patients at the same time of the15-1949R1 Gallo 12-7-15v2 8 day or adhering to standard procedures regarding the amount of clothing worn. While variations were 148 unlikely to systematically differ between study arms or visits, they could be expected to bias the results 149 toward the null of finding no difference between arms. Given the site's tropical climate, substantial 150 differences in clothing weight, though, was unlikely. Also, because weight was not a focus of the trial, 151 participants would have had no reason to attempt to manipulate their weight (e.g., by skipping meals) 152 before study visits. The retention rate of the cohort was excellent, with 94% of enrolled women 153 completing both follow-up visits. Furthermore, the randomized controlled design provides the strongest 154 type of evidence for evaluating the method's effects. 
